UCB Income Statement | StatInvestor

Health Care & Life Sciences » Biotechnology | UCB

UCB S.A. | Income Statement

Fiscal year is January-December. All values EUR Millions.

2013

2014

2015

2016

2017

2018

Sales/Revenue

3,133

3,344

3,876

4,147

4,530

4,632

Cost of Goods Sold (COGS) incl. D&A

965

1,054

1,158

1,202

1,200

1,198

Gross Income

2,168

2,290

2,718

2,945

3,330

3,434

SG&A Expense

1,882

1,908

2,134

2,144

2,193

2,309

EBIT

387

601

1,116

1,097

Unusual Expense

173

223

Non Operating Income/Expense

128

135

Interest Expense

150

145

Pretax Income

121

111

426

764

988

1,016

Income Tax

111

199

218

200

Consolidated Net Income

105

315

565

770

815

Net Income

115

264

543

752

792

Net Income After Extraordinaries

566

751

784

Net Income Available to Common

160

209

301

543

752

791

EPS (Basic)

0.88

1.10

3.25

2.76

4.00

4.24

Basic Shares Outstanding

182

190

192

188

EPS (Diluted)

0.88

1.10

3.24

2.76

4.00

4.24

Diluted Shares Outstanding

182

190

192

188

EBITDA

522

607

853

1,016

1,361

1,384

Other Operating Expense

Non-Operating Interest Income

Minority Interest Expense

About UCB

View Profile

Address	Allée de la Recherche, 60 Brussels BU 1070 Belgium
Employees	-
Website	http://www.ucb.com
Updated	07/08/2019
UCB SA engages in the research, development, and commercialization of pharmaceutical and biotechnology products. It offers medicinal products such as briviact, keppra, vimpat, neupro, cimzia, nootropil, xyrem, xyzal, and zyrtec. The company was founded by Emmanuel Janssen on January 18, 1928 and is headquartered in Brussels, Belgium.